Spruce Street Capital LP Invests $55.83 Million in Relay Therapeutics, Inc. $RLAY

Posted by Brenda Bartman on Aug 25th, 2026

Spruce Street Capital LP bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 2,984,125 shares of the company’s stock, valued at approximately $55,832,979. Relay Therapeutics accounts for 0.0% of Spruce Street Capital LP’s holdings, making the stock its 2nd largest position. Spruce Street Capital LP owned about 1.36% of Relay Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RLAY. Alphabet Inc. acquired a new stake in Relay Therapeutics in the 2nd quarter valued at $26,382,000. California State Teachers Retirement System grew its position in shares of Relay Therapeutics by 47.9% in the first quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock valued at $1,732,000 after purchasing an additional 56,422 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in Relay Therapeutics in the second quarter worth approximately $1,323,000. Sanctuary Advisors LLC bought a new position in Relay Therapeutics in the second quarter worth about $1,995,000. Finally, Bank of America Corp DE raised its stake in shares of Relay Therapeutics by 86.1% in the first quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock worth $19,280,000 after purchasing an additional 896,746 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Sanjiv Patel sold 48,199 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total transaction of $943,736.42. Following the sale, the chief executive officer directly owned 615,898 shares in the company, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Thomas Catinazzo sold 1,459 shares of the firm’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $18.61, for a total value of $27,151.99. Following the sale, the chief financial officer directly owned 158,285 shares in the company, valued at $2,945,683.85. The trade was a 0.91% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 6,409,639 shares of company stock valued at $123,633,399 in the last 90 days. 5.04% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Raymond James Financial reiterated a “strong-buy” rating on shares of Relay Therapeutics in a report on Tuesday, May 19th. Guggenheim reissued a “buy” rating on shares of Relay Therapeutics in a report on Friday, August 7th. JonesTrading upgraded shares of Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Wall Street Zen downgraded shares of Relay Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, Zacks Research raised shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday, August 20th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Relay Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $25.92.

Get Our Latest Research Report on RLAY

Relay Therapeutics Stock Down 3.6%

Shares of NASDAQ RLAY traded down $0.70 during midday trading on Friday, hitting $18.72. The stock had a trading volume of 1,606,409 shares, compared to its average volume of 3,161,390. Relay Therapeutics, Inc. has a 52 week low of $3.52 and a 52 week high of $21.27. The company has a market cap of $4.10 billion, a P/E ratio of -11.92 and a beta of 1.69. The business’s 50 day moving average is $19.21 and its 200-day moving average is $14.71.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. As a group, analysts expect that Relay Therapeutics, Inc. will post -1.61 EPS for the current fiscal year.

Relay Therapeutics Company Profile

(Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.